Abstract: A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating.

Abstract: A method for preparing a stable gatifloxacin composition in oral dosage form, said method comprising: (a) mixing gatifloxacin or a pharmaceutically acceptable salt or hydrate thereof, a disintegrant, and a filler for a time sufficient to form a mixture; (b) compacting the mixture of Step (a) at a compaction force of about 1 kN to about 30 kN for a time sufficient to form a compact; (c) milling the compact of Step (b) to form a granulation; and (d) mixing the granulation of Step (c) with an effective amount of a lubricant for a time sufficient to produce a gatifloxacin composition having a tap density of at least about 0.50 g/mL.

Abstract: A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating.

Abstract: An extended-release pharmaceutical composition comprising a core and a coating, wherein said core comprises propranolol or a pharmaceutically acceptable salt thereof and at least one excipient, and said coating comprises at least one water-soluble polymer and at least one water-insoluble polymer, wherein said coating is heated at a temperature of about 30° C. to about 70° C. after being applied to said core.

Abstract: A taste masked pharmaceutical composition comprising: (a) a core comprising a bitter tasting drug, such as cetirizine dihydrochloride; and (b) a coating comprising a pharmaceutically acceptable cationic co-polymer based on mono- or dialkylaminoalkyl methacrylate and neutral acrylic or methacrylic esters, wherein the alkyl group independently has 1 to 6 carbon atoms, wherein said coating is applied to the surface of said core. The taste masked pharmaceutical compositions of the invention may be prepared without using an organic solvent or a cyclodextrin.

Abstract: A pharmaceutical composition comprising a hydrophobic matrix comprised of paroxetine HCl and a lipid component is provided. The matrix also preferably contains hydrophilic polymers, e.g., hypromellose. This invention also relates to a method of making such a composition by melt granulating paroxetine HCl with a molten binder comprising a lipid component. This invention also relates to tablets which contain such a matrix as a core and which having an enteric coating surrounding said core.

Abstract: A pharmaceutical composition comprising microtablets, wherein said microtablets comprise lansoprazole, a lubricant, optionally one or more excipients, and an enteric coating, wherein the weight ratio of lansoprazole to lubricant is from about 1:4 to about 8:1, wherein said microtablets have a tablet size of about 1 mm to about 4 mm, and a tablet weight of 1 to 50 mg, and said microtablets are free of a separating or intermediate layer between the lansoprazole and enteric coating.

Abstract: The present invention provides a pharmaceutical composition having enhanced solubility comprising a drug and polyethylene glycol, wherein the ratio of polyethylene glycol to drug by weight is from about 0.2:1 to about 10:1, and the polyethylene glycol has a melting point of at least 37° C. The pharmaceutical compositions exhibit rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.